Edwards Lifesciences Corporation

Edwards Lifesciences Corporation's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Edwards Lifesciences Corporation has 576.60M shares outstanding.

As of June 30, 2026, Edwards Lifesciences Corporation maintains a current ratio of 4.52, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation posted a return on equity (ROE) of 9.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.62 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.85, useful for judging operating efficiency across full business cycles. The company generates approximately 357,380.33 in revenue per employee across its workforce of 15,950.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.27 indicates how many times Edwards Lifesciences Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation recorded 384.26M in income tax expense. That works out to an effective tax rate of 30.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.24B, leaving 879.59M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation generated 5.70B in revenue and converted that into 879.59M in net income, yielding earnings per share of 1.47. EBITDA reached 1.41B, while operating income came in at 1.60B.

As of June 30, 2026, Edwards Lifesciences Corporation holds 3.72B in cash and equivalents against 616.56M in total debt, resulting in a net debt position of -2.02B. Total book value stands at 9.29B, with working capital of 4.65B providing operational flexibility.

Edwards Lifesciences Corporation produced 1.51B in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 1.51B - equivalent to 2.60 per share.

Over the twelve months ended June 30, 2026, Edwards Lifesciences Corporation posted a gross margin of 77.84, reflecting its pricing power and cost economics. The operating margin of 28.09 and net profit margin of 15.43 provide insight into operational efficiency.

Edwards Lifesciences Corporation's most recent stock split took place on June 1, 2020 with a 1:3 split ratio.